undamentalytics Newsletter
Sign in

Tarsus Pharmaceuticals, Inc. balance sheet

At the end of fiscal 2025, Tarsus Pharmaceuticals, Inc. had total assets of $562m, total liabilities of $219m and shareholders' equity of $343m. It held $184m in cash against $75.0m of debt: net cash of $109m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMJun 2026
Cash and equivalents1681717222595184205
Receivables00017478596
Inventory——03344
Total current assets171176225256357523562
Total assets172179228265377562611
Accounts payable————91640
Deferred revenue (current)010————
Total current liabilities511153781136176
Long-term debt—01930727273
Total debt002030757575
Total liabilities6123569152219264
Shareholders' equity166167193197225343347
Net debt (negative = net cash)−168−171−52−195−20−109−130
Shares outstanding—21m27m34m38m43m43m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: MIRM vs TARSARWR vs TARSHCM vs TARS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Tarsus Pharmaceuticals, Inc.'s SEC filings (10-K and 10-Q), retrieved October 29, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Tarsus Pharmaceuticals, Inc.